Jan 05, 2024
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
Mar 12, 2020
Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer
Jan 13, 2020
Concerto HealthAI Establishes Real-World Data and AI Collaboration with Janssen
Feb 08, 2018
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 Data for Apalutamide and the Janssen Prostate Cancer Strategy and Portfolio
Jan 23, 2018
ChemDiv Announces Expansion of Multi-Year Hit Identification Collaboration with Janssen
Dec 28, 2017
Esketamine Phase 2 Data Published in JAMA Psychiatry Showed Significant Improvement of Depressive Symptoms in People with Treatment-Resistant Depression
Dec 11, 2017
Janssen Submits Supplemental New Drug Application to FDA Seeking New Indications for XARELTO® (rivaroxaban) for Patients with Chronic Coronary and/or Peripheral Artery Disease (CAD/PAD)
Dec 05, 2017
Phase 3 Study Evaluating IMBRUVICA® (ibrutinib) in Combination with Rituximab in Waldenström's Macroglobulinemia Met Primary Endpoint
Nov 15, 2017
New Janssen Healthy Minds Videos Explore Latest Alzheimer's Research and Perspectives of Caregiver with Risk for Dementia
Nov 07, 2017
New Phase 2 Data Show Treatment With TREMFYA® (guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year
Nov 06, 2017
STELARA® (ustekinumab) Shows Positive Results In Treatment Of Systemic Lupus Erythematosus In Phase 2 Trial
Oct 11, 2017
Janssen Research & Development Establishes First-of-Its-Kind Mobile Medication and Data Management Technology Platform for Industry Use
Oct 10, 2017
New Videos about Treatment-Resistant Depression Launch on World Mental Health Day to Bring Attention to Complex, Debilitating Condition
Oct 05, 2017
NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
Oct 02, 2017
Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
Sep 25, 2017
Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1
Sep 16, 2017
New Two-Year TREMFYA(TM) (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance
Aug 21, 2017
New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study
Jun 28, 2017
U.S. FDA Grants Priority Review of XARELTO® (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism (VTE)